JP6325530B2 - Ｎａｎｏ４６遺伝子、及び乳癌転帰を予測する方法 - Google Patents

Ｎａｎｏ４６遺伝子、及び乳癌転帰を予測する方法 Download PDF

Info

Publication number
JP6325530B2
JP6325530B2 JP2015514143A JP2015514143A JP6325530B2 JP 6325530 B2 JP6325530 B2 JP 6325530B2 JP 2015514143 A JP2015514143 A JP 2015514143A JP 2015514143 A JP2015514143 A JP 2015514143A JP 6325530 B2 JP6325530 B2 JP 6325530B2
Authority
JP
Japan
Prior art keywords
breast cancer
tumor
expression
luminal
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015514143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518724A (ja
JP2015518724A5 (enExample
Inventor
エム．フェリー ショーン
エム．フェリー ショーン
エス．パーカー ジョエル
エス．パーカー ジョエル
ジャスティン ストーホフ ジェイムズ
ジャスティン ストーホフ ジェイムズ
エム．ペロウ チャールズ
エム．ペロウ チャールズ
ジェイ．エリス マシュー
ジェイ．エリス マシュー
エス．バーナード フィリップ
エス．バーナード フィリップ
オー．ニールセン トルステン
オー．ニールセン トルステン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2015518724A publication Critical patent/JP2015518724A/ja
Publication of JP2015518724A5 publication Critical patent/JP2015518724A5/ja
Application granted granted Critical
Publication of JP6325530B2 publication Critical patent/JP6325530B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015514143A 2012-05-22 2013-05-22 Ｎａｎｏ４６遺伝子、及び乳癌転帰を予測する方法 Active JP6325530B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261650209P 2012-05-22 2012-05-22
US61/650,209 2012-05-22
US201361753673P 2013-01-17 2013-01-17
US61/753,673 2013-01-17
PCT/US2013/042157 WO2013177245A2 (en) 2012-05-22 2013-05-22 Nano46 genes and methods to predict breast cancer outcome

Publications (3)

Publication Number Publication Date
JP2015518724A JP2015518724A (ja) 2015-07-06
JP2015518724A5 JP2015518724A5 (enExample) 2017-12-28
JP6325530B2 true JP6325530B2 (ja) 2018-05-16

Family

ID=49624503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514143A Active JP6325530B2 (ja) 2012-05-22 2013-05-22 Ｎａｎｏ４６遺伝子、及び乳癌転帰を予測する方法

Country Status (12)

Country Link
US (3) US20130337444A1 (enExample)
EP (1) EP2852689B1 (enExample)
JP (1) JP6325530B2 (enExample)
CN (2) CN111500718A (enExample)
AU (1) AU2013266419B2 (enExample)
BR (1) BR112014029300A2 (enExample)
CA (1) CA2874492C (enExample)
ES (1) ES2763931T3 (enExample)
IL (1) IL235795B (enExample)
IN (1) IN2014MN02418A (enExample)
MX (1) MX369628B (enExample)
WO (1) WO2013177245A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
EP2785873A4 (en) 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
DK3511423T4 (da) 2012-10-17 2024-07-29 Spatial Transcriptomics Ab Fremgangsmåder og produkt til optimering af lokaliseret eller rumlig detektion af genekspression i en vævsprøve
US20160115551A1 (en) * 2013-05-13 2016-04-28 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
EP4234716A3 (en) 2013-06-25 2023-12-06 Prognosys Biosciences, Inc. Methods for determining spatial patterns of biological targets in a sample
AU2014317843A1 (en) * 2013-09-09 2016-03-24 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
CN113403373B (zh) 2014-11-21 2025-04-11 布鲁克空间生物学公司 无酶且无扩增的测序
SG11201704177SA (en) 2014-11-24 2017-06-29 Nanostring Technologies Inc Methods and apparatuses for gene purification and imaging
JP2018500895A (ja) * 2014-12-09 2018-01-18 キングス・カレッジ・ロンドン タキサン療法による乳癌治療
EP4119677B1 (en) 2015-04-10 2023-06-28 Spatial Transcriptomics AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US20180209981A1 (en) * 2015-07-23 2018-07-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
CN109715825B (zh) 2016-05-16 2023-01-06 纳米线科技公司 用于检测样品中目标核酸的方法
WO2017222453A1 (en) 2016-06-21 2017-12-28 Hauling Thomas Nucleic acid sequencing
WO2018074865A2 (ko) * 2016-10-21 2018-04-26 서울대학교병원 유방암 예후 예측용 조성물 및 방법
JP6730525B2 (ja) 2016-11-21 2020-07-29 ナノストリング テクノロジーズ，インコーポレイティド 化学組成物とそれを利用する方法
KR101950717B1 (ko) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 유방암 환자의 화학치료 유용성 예측 방법
WO2018144782A1 (en) * 2017-02-01 2018-08-09 The Translational Genomics Research Institute Methods of detecting somatic and germline variants in impure tumors
CN120210336A (zh) 2017-10-06 2025-06-27 10X基因组学有限公司 Rna模板化连接
KR102071491B1 (ko) * 2017-11-10 2020-01-30 주식회사 디시젠 차세대 염기서열분석을 이용한 기계학습 기반 유방암 예후 예측 방법 및 예측 시스템
EP3794146B1 (en) 2018-05-14 2025-12-10 Bruker Spatial Biology, Inc. Method for identifying a predetermined nucleotide sequence
WO2020094399A1 (en) * 2018-11-05 2020-05-14 Biontech Diagnostics Gmbh Predictive methods in breast cancer
CN113906147B (zh) 2019-05-31 2024-09-13 10X基因组学有限公司 检测目标核酸分子的方法
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
GB201919032D0 (en) 2019-12-20 2020-02-05 Cartana Ab Method of detecting an analyte
JP2023514749A (ja) 2020-02-21 2023-04-07 １０エックス ジェノミクス インコーポレイテッド 統合型インサイチュ空間的アッセイのための方法および組成物
US12209273B2 (en) 2020-06-12 2025-01-28 10X Genomics, Inc. Nucleic acid assays using click chemistry bioconjugation
EP3945136A1 (en) * 2020-07-28 2022-02-02 Hospital Clínic de Barcelona In vitro method for the prognosis of patients suffering from her2-positive breast cancer
US12297499B2 (en) 2020-08-17 2025-05-13 10X Genomics, Inc. Multicomponent nucleic acid probes for sample analysis
US12060603B2 (en) 2021-01-19 2024-08-13 10X Genomics, Inc. Methods for internally controlled in situ assays using padlock probes
CA3248919A1 (en) * 2021-12-20 2023-06-29 Fundacio De Recerca Clinic Barcelona Inst D’Investigacions Biomediques August Pi I Sunyer DEVELOPMENT AND VALIDATION OF AN IN VITRO PROGNOSIS FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER
CN117965734B (zh) * 2024-02-02 2024-09-24 奥明星程(杭州)生物科技有限公司 一种用于检测硬纤维瘤的基因标志物、试剂盒、检测方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US20020168639A1 (en) * 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
WO2005039382A2 (en) * 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
CA2540167A1 (en) * 2003-09-29 2005-05-12 Pathwork Informatics, Inc. Systems and methods for detecting biological features
WO2006010150A2 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
CN101061480A (zh) * 2004-09-22 2007-10-24 三路影像公司 用来分析和优化用于癌症诊断的标记候选物的方法和计算机程序产品
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
EP1963531B1 (en) * 2005-12-23 2011-09-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
JP5700911B2 (ja) 2005-12-23 2015-04-15 ナノストリング テクノロジーズ，インコーポレーテッド 配向され、固定化された巨大分子を含む組成物とその製造法
CA2687292C (en) 2007-04-10 2017-07-04 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
EP2195467B1 (en) * 2007-09-06 2016-12-14 bioTheranostics, Inc. Tumor grading and cancer prognosis in breast cancer
PL2297359T4 (pl) * 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
ES2614810T3 (es) 2008-08-14 2017-06-02 Nanostring Technologies, Inc Nanoindicadores estables
MX2012011167A (es) * 2010-03-31 2013-02-07 Sividon Diagnostics Gmbh Metodo para prediccion de recurrencia de cancer de mama bajo tratamiento endocrino.

Also Published As

Publication number Publication date
IL235795B (en) 2020-02-27
US20230272476A1 (en) 2023-08-31
JP2015518724A (ja) 2015-07-06
EP2852689A4 (en) 2016-05-11
MX2014014275A (es) 2015-07-06
EP2852689B1 (en) 2019-12-11
BR112014029300A2 (pt) 2017-07-25
EP2852689A2 (en) 2015-04-01
US20200332368A1 (en) 2020-10-22
MX369628B (es) 2019-11-14
US20130337444A1 (en) 2013-12-19
CA2874492A1 (en) 2013-11-28
AU2013266419A1 (en) 2014-12-11
IL235795A0 (en) 2015-01-29
WO2013177245A2 (en) 2013-11-28
ES2763931T3 (es) 2020-06-01
CN104704128A (zh) 2015-06-10
CN111500718A (zh) 2020-08-07
IN2014MN02418A (enExample) 2015-08-14
CA2874492C (en) 2021-10-19
WO2013177245A3 (en) 2015-01-29
AU2013266419B2 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
JP6325530B2 (ja) Ｎａｎｏ４６遺伝子、及び乳癌転帰を予測する方法
US20230250484A1 (en) Gene expression profiles to predict breast cancer outcomes
JP5971769B2 (ja) アントラサイクリン療法を用いて乳癌を処置する方法
US20140154681A1 (en) Methods to Predict Breast Cancer Outcome
JP6144695B2 (ja) タキサン療法を用いて乳癌を処置する方法
JP2015530072A (ja) ゲムシタビン療法による乳癌の治療方法
US20150024399A1 (en) Molecular diagnosis and typing of lung cancer variants
JP2016519935A (ja) 結節陽性の初期乳癌における再発リスクを予測する方法
US20150072021A1 (en) Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy
JP2016521979A (ja) 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
EP2278026A1 (en) A method for predicting clinical outcome of patients with breast carcinoma
JP2018500895A (ja) タキサン療法による乳癌治療
AU2016228291A1 (en) Gene Expression Profiles to Predict Breast Cancer Outcomes

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170815

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20171115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180412

R150 Certificate of patent or registration of utility model

Ref document number: 6325530

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250